Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

ImmuPharma PLC (IMM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.04 0.00    0.00%
01:35:59 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 477,122
  • Bid/Ask: 2.00 / 2.10
  • Day's Range: 2.01 - 2.10
Type:  Equity
Market:  United Kingdom
ISIN:  GB0033711010 
SEDOL:  3371101
ImmuPharma 2.04 0.00 0.00%

ImmuPharma PLC Company Profile

 
Get an in-depth profile of ImmuPharma PLC, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

13

Equity Type

ORD

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company’s lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Contact Information

Address 1 Bartholomew Close
London, EC1A 7BL
United Kingdom
Phone 44 20 7206 2650
Fax -

Top Executives

Name Age Since Title
Timothy Paul McCarthy 65 2015 Chairman & CEO
Lisa Baderoon - 2012 Head of Investor Relations & Non Executive Director
Timothy Gary Franklin - 2020 COO & Director
Daniel J. Wallace - 2013 Member of Scientific Advisory Board
Lee S. Simon 72 2013 Member of Scientific Advisory Board
Vibeke S. Strand - 2013 Member of Scientific Advisory Board
David A. Isenberg - 2013 Member of Scientific Advisory Board
Cees GM Kallenberg - 2013 Member of Scientific Advisory Board
Sébastien R. Goudreau - 2022 CEO of ImmuPharma Biotec & Director
Laurence Reilly - 2023 Senior independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IMM Comments

Write your thoughts about ImmuPharma PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email